Cerebral Venous Sinus Thrombosis Clinical Trial
— CCCOfficial title:
Cerebral Venous Thrombosis Cohort Study in China Mainland
This study was aimed to reveal the clinical features,natural history of the diseases and current therapeutic situations of cerebral venous thrombosis (CVT) in China mainland. Blood samples and cerebrospinal fluid samples will be collected after recruitment to reveal the pathological mechanisms of CVT and identify the biomarkers for CVT.
Status | Not yet recruiting |
Enrollment | 3000 |
Est. completion date | May 31, 2029 |
Est. primary completion date | May 31, 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: • Cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis diagnosed by digital subtraction angiography (DSA), magnetic resonance venography (MRV), computed tomography venography (CTV) or high-resolution magnetic resonance imaging (HR-MRI). Exclusion Criteria: • None of the patient, trustee or immediate family members signed the informed consent. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Capital Medical University | Beijing Municipal Science & Technology Commission |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Death rate | A combination of death form of all causes | 1 year from baseline | |
Primary | Functional independence | Defined as modified Rankin score (0-5) equal to or lower than 2 | 1 year from baseline | |
Primary | Recurrence of cerebral venous sinus thrombosis, deep cerebral venous thrombosis and cortical vein thrombosis | Diagnosed by DSA, MRV, CTV or HR-MRI | 1 year from baseline | |
Primary | Incidence of hemorrhagic complication | Extracranial hemorrhage (fall in hemoglobin of 2 gram/dl or more within 48 hours) or intracranial hemorrhage | 1 year from baseline | |
Primary | Incidence of sinus wall rupture | 1 year from baseline | ||
Primary | Incidence of acute ischemic stroke | 1 year from baseline | ||
Primary | Incidence of acute myocardial infarction | 1 year from baseline | ||
Primary | Incidence of pulmonary embolism | 1 year from baseline | ||
Primary | Incidence of deep venous thrombosis | 1 year from baseline | ||
Secondary | Incidence of epilepsy | 1 year from baseline | ||
Secondary | Incidence of allergic reaction | 1 year from baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04269954 -
The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis
|
Phase 4 | |
Recruiting |
NCT03273179 -
Cerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment Scales
|
N/A | |
Recruiting |
NCT05291585 -
The Dedicated Venous Sinus Thrombectomy Stent for Endovascular Treatment of Cerebral Venous Sinus Thrombosis.
|
N/A | |
Recruiting |
NCT04966182 -
Application CT and MRI in Cerebral Venous Sinus Thrombosis
|
||
Recruiting |
NCT05021198 -
The Norwegian Cerebral Venous Thrombosis Study
|
||
Withdrawn |
NCT04580238 -
Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache
|
Phase 1 | |
Completed |
NCT05448248 -
Multicenter Registry Study Of Cerebral Venous Thrombosis In China (RETAIN-CH)
|